These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 16788150

  • 1. Slow start to phase 0 as researchers debate value.
    Twombly R.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):804-6. PubMed ID: 16788150
    [No Abstract] [Full Text] [Related]

  • 2. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D.
    Drug Discov Today; 2006 Mar 21; 11(5-6):185-6. PubMed ID: 16580594
    [Abstract] [Full Text] [Related]

  • 3. The role of the National Cancer Institute in drug development.
    Doroshow J.
    Clin Adv Hematol Oncol; 2005 Apr 21; 3(4):257-8. PubMed ID: 16166997
    [No Abstract] [Full Text] [Related]

  • 4. Adaptive trials receive boost.
    Jones D.
    Nat Rev Drug Discov; 2010 May 21; 9(5):345-8. PubMed ID: 20414200
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep 15; 96(18):1355. PubMed ID: 15367566
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R.
    J Natl Cancer Inst; 2005 May 18; 97(10):708-9. PubMed ID: 15900036
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increasing access to investigational drugs.
    Christian M.
    Clin Adv Hematol Oncol; 2004 Feb 18; 2(2):90-1. PubMed ID: 16163167
    [No Abstract] [Full Text] [Related]

  • 14. Cancer drugs. Weighing the risks and benefits.
    Bren L.
    FDA Consum; 2007 Feb 18; 41(1):10-9. PubMed ID: 17342832
    [Abstract] [Full Text] [Related]

  • 15. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar 18; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 16. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA, Allen JD, Sigal EV.
    Health Aff (Millwood); 2011 Jul 20; 30(7):1375-81. PubMed ID: 21680577
    [Abstract] [Full Text] [Related]

  • 19. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
    Tuma RS.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):810-1. PubMed ID: 16788154
    [No Abstract] [Full Text] [Related]

  • 20. EU law mandates drug testing in children.
    Sinha G.
    J Natl Cancer Inst; 2008 Jan 16; 100(2):84-5. PubMed ID: 18182609
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.